Equity Sector Funds Very High Risk Fund Managers: Nimesh Chandan, Sorbh Gupta, Siddharth Chaudhary
Equity Sector Funds Very High Risk
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -4.07% | -5.43% | -4.88% | -5.85% | 1.57% | 0% | 0% | 0% | 0% | 0% | -7.15% |
| Category returns | -4.62% | -4.15% | -3.61% | -4.88% | 2.01% | 8.35% | 21.98% | 13.89% | 14.12% | 12.46% | N/A |
| Absolute returns | -4.07% | -5.43% | -4.88% | -5.85% | 1.57% | 0% | 0% | 0% | 0% | 0% | -8.93% |
| Rank within category | 5 | 13 | 10 | 10 | 10 | 15 | 11 | 11 | 10 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -4.58% | -6.2% |
| Q1 returns | N/A | -10.08% | -5.84% |
| Q2 returns | N/A | 6.76% | -0.37% |
| Q3 Returns | N/A | -2.45% | N/A |
| Q4 Returns | N/A | 1.89% | N/A |
Expense ratio: 2.39%
Inclusive of GST
Exit load
1% on or before 3M, Nil after 3M
| Alpha | -0.647862 |
| Beta | 0.6357 |
| Sharpe Ratio | -0.23077 |
| Sortino Ratio | -0.348014 |
| R-Squared | 0.3982 |
| Tracking Error | 3.0822 |
| Downside Risk | 15.0167 |
| Std. Deviation (Annualised) | 12.4902 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | -4.98% | -8.04% | -5.94% | -7.06% | 1.13% | 25.21% | 16.1% | 0% | 18.3% | 6,801.16 | 1.86 | 0.41 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -3.62% | -1.34% | -1.04% | -3.85% | 1.16% | 24.15% | 16.31% | 12.04% | 16.08% | 4,076.67 | 1.93 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -4.47% | -4.44% | -5.3% | -4.52% | 2.87% | 23.75% | 14.19% | 12.19% | 14.39% | 1,106.71 | 2.27 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -3.62% | -0.99% | 0.23% | -0.86% | 3.59% | 23.39% | 15.03% | 0% | 18.72% | 2,843.74 | 1.93 | 0.36 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -3.62% | -2.05% | -1.76% | -1.73% | 3.87% | 22.48% | 13.16% | 0% | 17.78% | 854.04 | 2.30 | 0.36 | Very High |
| Nippon India Pharma Fund - Growth | -5.26% | -4.16% | -2.63% | -5.68% | 2.94% | 21.68% | 14.06% | 14.03% | 19.49% | 8,306.35 | 1.81 | 0.35 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -6.37% | -6.81% | -7.01% | -6.57% | -0.76% | 20.94% | 13.67% | 11.59% | 10.59% | 1,300.81 | 2.11 | 0.33 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.14% | -7.8% | -6.12% | -7.34% | -3.35% | 20% | 13.53% | 0% | 19.14% | 3,033.42 | 1.94 | 0.32 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -4.73% | -6.11% | -5.78% | -5.89% | -3.31% | 19.95% | 11.02% | 0% | 15.24% | 82.13 | 2.36 | 0.31 | Very High |
| Bajaj Finserv Healthcare Fund - Regular Plan - Growth Current | -4.07% | -5.43% | -4.88% | -5.85% | 1.57% | 0% | 0% | 0% | -7.15% | 314.74 | 2.39 | -0.22 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 97.53% |
| Domestic Mutual Funds Units | 1.62% | |
| Cash & Cash Equivalents and Net Assets | 0.84% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 64.77% | |
| Healthcare Services | 19.52% | |
| Food Products | 2.01% | |
| Chemicals & Petrochemicals | 1.99% | |
| Personal Products | 2.89% | |
| Others | 2.47% | |
| Industrial Products | 1.54% | |
| Retailing | 1.39% | |
| Insurance | 1.18% | |
| Diversified FMCG | 1.16% | |
| Agricultural Food & other Products | 1.09% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.21% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.40% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 6.80% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.21% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.93% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.46% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 4.40% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.79% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.70% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.60% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.40% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.65% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.45% |
| Zydus Wellness Ltd. | Food Products | Domestic Equities | 2.00% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.99% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.98% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 1.97% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.94% |
| Godrej Consumer Products Ltd. | Personal Products | Domestic Equities | 1.93% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.88% |
| Bajaj Finserv Money Market Fund-Direct Plan-Growth | Domestic Mutual Funds Units | 1.62% | |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.57% |
| Shaily Engineering Plastics Ltd. | Industrial Products | Domestic Equities | 1.54% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.46% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.42% |
| Medplus Health Services Ltd. | Retailing | Domestic Equities | 1.39% |
| Medi Assist Healthcare Services Ltd. | Insurance | Domestic Equities | 1.18% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.18% |
| Hindustan Unilever Ltd. | Diversified FMCG | Domestic Equities | 1.16% |
| Tata Consumer Products Ltd. | Agricultural Food & other Products | Domestic Equities | 1.09% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.08% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.02% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.96% |
| Emami Ltd. | Personal Products | Domestic Equities | 0.95% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.92% |
| Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.90% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 0.72% | |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.13% | |
| Kwality Wall's (India) Ltd. | Food Products | Domestic Equities | 0.01% |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 0.27%
3-year: 0%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹9.04 (approx.) for the Bajaj Finserv Healthcare Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹315 Cr.
The expense ratio for the Regular Plan is 2.39.
1% on or before 3M, Nil after 3M.
Minimum SIP starts at ₹100.
The minimum lump sum investment is ₹500. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Nimesh Chandan, Sorbh Gupta, Siddharth Chaudhary
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
